Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with neutropenic fever who have existing malignancy or have undergone hematopoietic stem cell transplantation~* Requires hospitalization for intravenous (IV) empiric antibiotic therapy~Exclusion Criteria:~* Fungal or viral infection requiring additional therapy~* Known acute viral hepatitis~* Known to be human immunodeficiency virus (HIV) positive~* Expected requirement for hemodialysis while on study therapy~* Received \>24 hours of systemic antibacterial therapy within 72 hours of initiation of inpatient IV study drug~* Past or current history of epilepsy or seizure disorder~* Evidence of immediately life-threatening disease, progressively fatal disease, or life expectancy of 3 months or less.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAZ-AVI + Vancomycin or Linezolid (Type: EXPERIMENTAL): Ceftazidime-Avibactam (CAZ-AVI) 2.5 mg intravenous (IV) infusion every 8 hours for 5 to 14 days, duration determined by the investigator, plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local standard of care \[SOC\]) may be allowed after at least 72 hours (ie, minimum of 9 doses for CAZ-AVI) of inpatient IV study drug.
- Standard of Care+Vancomycin or Linezolid (Type: ACTIVE_COMPARATOR): Standard of Care (cefepime 2 g IV infusion every 8 hours or meropenem 1 g IV infusion every 8 hours or piperacillin/tazobactam 4.5 g IV infusion every 6 hours for 5 to 14 days, duration determined by the investigator) plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local SOC) may be allowed after at least 72 hours (ie, minimum of 9 doses for SOC therapies, except piperacillin/tazobactam, which is a minimum of 12 doses) of inpatient IV study drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).